Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2025-12-26 @ 9:57 PM
Study NCT ID:
NCT02186769
Status:
COMPLETED
Last Update Posted:
2015-06-18
First Post:
2014-06-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
Sponsor:
Luye Pharma Group Ltd.
Organization:
Study Overview
Official Title:
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg or 50 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A review of the amount of drug in your blood over time.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: